It operates in the world of health and science. It has 68 employees. Now — the numbers.
This is an established company with proven profits.
Revenue is spread across several lines; no single product carries the company.
No real growth (3% a year). Red columns mark years that ended in a loss.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 54% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 46% — still a thick cushion, though costs have been eating into it lately.
Over the last 3 years, sales grew about 11% a year on average.
There is $733.5M in the vault; even if every debt were paid off, $277.8M would remain.
The stock sits at $0.04. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
On our five-subject report card, LGNYZ sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: LGNYZ is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.